Omalizumab: living up to PROMises
- PMID: 30604545
- DOI: 10.1111/bjd.17314
Omalizumab: living up to PROMises
Comment on
-
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.Br J Dermatol. 2019 Jan;180(1):56-66. doi: 10.1111/bjd.16904. Epub 2018 Sep 17. Br J Dermatol. 2019. PMID: 29927483 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
